Loading clinical trials...
Loading clinical trials...
A Phase II Randomized, Double-Blind, Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
Conditions
Interventions
RO 205-2349
Locations
46
United States
Hollywood, Florida, United States
Durham, North Carolina, United States
Morrisville, North Carolina, United States
Portland, Oregon, United States
Portland, Oregon, United States
Camp Hill, Pennsylvania, United States
Start Date
June 1, 2003
Primary Completion Date
March 1, 2004
Completion Date
March 1, 2004
Last Updated
April 28, 2023
NCT05398783
NCT07224321
NCT07395050
NCT01399385
NCT07457580
NCT06513026
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions